{"id":12724,"date":"2026-02-02T18:37:30","date_gmt":"2026-02-02T15:37:30","guid":{"rendered":"https:\/\/nesiller.com\/hereditary-cancer-panel-focus-hereditary\/"},"modified":"2026-10-20T14:15:19","modified_gmt":"2026-10-20T11:15:19","slug":"empower-hereditary-cancer-panel","status":"publish","type":"page","link":"https:\/\/nesiller.com\/en\/oncology\/empower-hereditary-cancer-panel\/","title":{"rendered":"Empower\u2122 Hereditary Cancer Panel"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Oncology<\/a><\/div>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Empower\u2122\n
\nHereditary Cancer Panel<\/h1>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Understanding Your Hereditary Cancer Risk Is the First Step Toward Protecting Your Future and the Future of Your Loved Ones.<\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tTest brochure<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSample report<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Empower<\/a>\u2122<\/strong>, developed by Natera<\/strong>, is a comprehensive germline genetic test that evaluates genetic alterations associated with hereditary cancer syndromes. The analysis is performed using a blood sample at Natera\u2019s laboratory in the United States<\/strong>, helping assess an individual\u2019s hereditary cancer risk and supporting the planning of early detection, screening, and risk management strategies<\/strong>.<\/p>

Empower\u2122 is used not only for hereditary cancer risk assessment but also to help identify inherited biomarkers that may influence treatment decisions in individuals diagnosed with cancer. In particular, alterations detected in BRCA1<\/strong>, BRCA2<\/strong>, and genes associated with Lynch syndrome<\/strong> may support the evaluation of targeted treatment options.<\/p>

Identifying genetic variants associated with hereditary cancers enables risk assessment for both individuals and their family members. To provide a more comprehensive molecular profile, Empower\u2122 can also be used alongside somatic genomic profiling tests such as FOCUS CGP<\/strong><\/a> veya Altera\u2122<\/strong><\/a> .<\/p>

Cancer Types:<\/strong><\/p>

Breast, Ovarian, Endometrial (Uterine), Colorectal, Gastric, Prostate, Pancreatic, and Melanoma.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t
Feature<\/strong><\/th>Details<\/strong><\/th><\/tr><\/thead>

Who Should Be Tested?<\/strong><\/p><\/td>

  • Individuals diagnosed with cancer at or before the age of 50;<\/li>
  • Individuals with a family history of cancer or multiple cancers\/tumors on the same side of the family;<\/li>
  • Individuals concerned about their personal or family history of cancer.<\/li><\/ul><\/td><\/tr>

Cancer Type<\/strong><\/p><\/td>

\u00a0Hereditary Cancers<\/p><\/td><\/tr>

Sample Type<\/strong><\/td>

Blood (EDTA Tube)<\/p><\/td><\/tr>

Method<\/strong><\/td>

\u00a0Next-Generation Sequencing (NGS)<\/p><\/td><\/tr>

Coverage<\/strong><\/td>

81 Genes<\/span><\/p><\/td><\/tr>

Turnaround Time (TAT)<\/strong><\/td>

2\u20133 Weeks<\/p><\/td><\/tr><\/tbody><\/table>

* Genetic counseling is included as part of this test.
** BRCA1\/2 MLPA analysis and the Lynch syndrome panel are included in this test.
*** The panel content can be customized based on clinical findings, family history, and genetic counseling. A detailed gene list is available upon request.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Oncology Empower\u2122 Hereditary Cancer Panel Understanding Your Hereditary Cancer Risk Is the […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":12725,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-12724","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/12724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/comments?post=12724"}],"version-history":[{"count":61,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/12724\/revisions"}],"predecessor-version":[{"id":21602,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/12724\/revisions\/21602"}],"up":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/12725"}],"wp:attachment":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/media?parent=12724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}